Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis

Next Previous
Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Diphenhydramine; Methylprednisolone; Mycophenolate mofetil; Mycophenolate mofetil; Paracetamol; Prednisone
  • Indications Lupus nephritis
  • Focus Registrational; Therapeutic Use
  • Acronyms LUNAR
  • Sponsors Genentech; Roche

Most Recent Events

  • 15 Nov 2023 Initial post hoc analysis of patients in the control arms of the LUNAR and BELONG trial presented at the ACR Convergence 2023
  • 01 Mar 2023 Results comparing differences between B-cell depletion in lupus nephritis patient populations who received rituximab (LUNAR), ocrelizumab (BELONG), or obinutuzumab (NOBILITY), published in the Clinical Immunology
  • 24 Oct 2018 Results assessing changes in blood pressure and proteinuria of this and LUNAR trial from baseline to 1-year in patients with lupus nephritis, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top